Anupam Rasayan India has achieved a groundbreaking milestone by becoming the first company globally to commercialize ETFA (Ethyl Trifluoroacetate) production using its proprietary continuous flow chemistry platform. The company officially launched ETFA on June 11, 2026, positioning itself as a global leader in manufacturing ETFA at commercial scale using flow technology. This innovative process offers enhanced safety, efficiency, and sustainability compared to conventional batch processes, with significantly enhanced process safety, superior reproducibility, improved scalability, higher operational efficiency, and a lower environmental footprint. The achievement represents a significant advancement in the specialty chemicals sector, particularly in the domain of complex fluorination chemistry.
ETFA serves as a critical fluorinated building block and reagent used in the synthesis of organic fluorine compounds across life sciences, pharmaceuticals, and performance materials. The global addressable market for ETFA is estimated at approximately $500-600 million, highlighting its strategic importance within the specialty chemicals value chain. These compounds play vital roles in enhancing product performance, efficacy, and stability across various applications, with the product being launched in multiple countries including the USA and Japan, among others. ETFA is classified as a Chemical Intermediate and is integral to advancements across the life sciences, pharmaceutical, and performance materials industries, where fluorine chemistry plays a crucial role.
Anupam Rasayan shares opened higher on Friday, June 12, following the ETFA commercialization announcement, with the stock making an intraday opening high of ₹1,299 before cooling off from those levels. The stock now trades 0.2% higher at ₹1,260, though it has given up all initial gains during the session. Despite recent volatility, the stock has maintained its strong performance trajectory, with shares delivering multibagger returns, surging from ₹632.40 to ₹1,258 since February 2025, resulting in a massive gain of nearly 100%. The stock scaled a fresh record high of ₹1,415 and ended 2025 with gains of 82%, marking its biggest annual surge since listing. However, the stock is now down 7% in the last one month, resulting in a negative performance on a year-to-date basis as well.
Anand Desai, Managing Director of Anupam Rasayan, emphasized that the successful commercialization demonstrates the company's technological capabilities and ability to develop scalable solutions. According to the company statement, innovation remains at the core of their growth strategy, with continued investment planned in cutting-edge process technologies, research capabilities, and sustainable manufacturing practices to create long-term value for customers and stakeholders. The achievement not only demonstrates their technological capabilities in complex fluorination chemistry but also highlights their ability to develop and scale differentiated manufacturing solutions that address evolving customer requirements.
Incorporated in 1984, Anupam Rasayan is recognized as a leading player in custom synthesis (CSM) and the manufacturing of specialty chemicals in India. The company operates across two key verticals: Life Science related Specialty Chemicals (including Agrochemicals, Personal Care, and Pharmaceuticals) and Performance Materials (comprising Electronics & EV Chemicals and Polymers). As of March 31, 2026, the company operates eight manufacturing facilities across India and the USA, with an aggregate installed capacity of approximately 66,000 MT. Anupam serves a diverse client base of over 75 domestic and international customers, including 31 multinational corporations, catering to both domestic and international markets with its innovative ETFA production technology.
